JSM 2005 Online Program

Abstract #304096

This is the preliminary program for the 2005 Joint Statistical Meetings in Minneapolis, Minnesota. Currently included in this program is the "technical" program, schedule of invited, topic contributed, regular contributed and poster sessions; Continuing Education courses (August 7-10, 2005); and Committee and Business Meetings. This on-line program will be updated frequently to reflect the most current revisions.

To View the Program:
You may choose to view all activities of the program or just parts of it at any one time. All activities are arranged by date and time.

The views expressed here are those of the individual authors
and not necessarily those of the ASA or its board, officers, or staff.

The Program has labeled the meeting rooms with "letters" preceding the name of the room, designating in which facility the room is located:

Minneapolis Convention Center = “MCC” Hilton Minneapolis Hotel = “H” Hyatt Regency Minneapolis = “HY”

Back to main JSM 2005 Program page

Legend:

= Applied Session,

= Theme Session,

= Presenter

Activity Number:	223
Type:	Topic Contributed
Date/Time:	Tuesday, August 9, 2005 : 8:30 AM to 10:20 AM
Sponsor:	Biometrics Section
Abstract - #304096
Title:	Use of Multiple Imputation and Other Techniques To Assess Impact of Censoring by Loss to Followup in Clinical Trials
Author(s):	Barry Davis*+
Companies:	The University of Texas Health Science Center at Houston
Address:	1200 Herman Pressler, Houston, TX, 77030, United States
Keywords:	Multiple Imputation ; Censoring ; Survival Analysis
Abstract:	Large long-term trials are done to assess risks and benefits of treatments. The consequences of losses to followup can be great, especially if results are used for policy statements or treatment guidelines. Sensitivity analyses should assess the impact of losses.The following can be compared: hazard ratio (HR) estimates (and their significance) for treatment effects from intent to treat analyses, HRs obtained using multiple imputation, HRs from analyses excluding losses, and HRs excluding small subsets of data that maintain the randomization scheme. An example will be presented from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a randomized double-blind, active-controlled clinical trial in hypertensive patients designed to determine if treatment with newer Antihypertensive agents reduces coronary heart disease incidence compared to a diuretic. Randomization to treatment was stratified by center. Mean follow-up was 4.9 years, and 99% of expected person-years were observed. The suggested analyses were performed, and all were consistent with the trial's published conclusions. The results and their implications will be presented.

The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.

Back to the full JSM 2005 program